Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3&apos;,5&apos;-cyclic monophosphate provides a biological means for control of human colon cancer cell growth. by Ally, S et al.
Proc. Natl. Acad. Sci. USA
Vol. 85, pp. 6319-6322, September 1988
Biochemistry
Selective modulation of protein kinase isozymes by the site-selective
analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a
biological means for control of human colon cancer cell growth
(cAMP receptor proteins/nuclear translocation/gene transcription)
SHAMSIA ALLY*, GIAMPAOLO TORTORA*, TIMOTHY CLAIR*, DOMENICO GRIECOt, GIORGIO MERLOt,
DIONYssIos KATSAROS*, DAGFINN OGREID§, STEIN 0. DOSKELAND§, TORE JAHNSEN¶,
AND YOON SANG CHO-CHUNG*II
*Cellular Biochemistry Section and tOncogenetics Section, Laboratory of Tumor Immunology and Biology, National Cancer Institute, and tClinical
Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892; §Cell Biology
Group, Institute of Anatomy, University of Bergen, Bergen, Norway; and lInstitute of Pathology, Rikshospitalet, Oslo, Norway
Communicated by Van Rensselaer Potter, May 26, 1988
ABSTRACT Differential expression of type I and type II
cAMP-dependent protein kinase isozymes has been linked to
growth regulation and differentiation. We examined the
expression of protein kinase isozymes in the LS 174T human
colon cancer cell line during 8-chloroadenosine 3',5'-cyclic
monophosphate (8-Cl-cAMP)-induced growth inhibition. Two
species of R" (the regulatory subunit of protein kinase type II)
with apparent Mr 52,000 (RI) andMr 56,000 (RS) and a single
species of R' (the regulatory subunit of protein kinase type I)
with Mr 48,000 were identified in the cancer cells. R' and both
forms of R" were covalently labeled with 8-azidoadenosine
3',5'-cyclic [32P]monophosphate, and two anti-R' antibodies
that exclusively recognize either Rsl or Rs resolved two forms
of the R" receptors. 8-Cl-cAMP treatment induced a decrease
of R' and an increase of both Rs and R16 in the cytosols of
cancer cells and rapid translocation (within 10 min) of R5 from
the cytosol to nucleus. 8-Cl-cAMP caused transcriptional
activation of the Rs receptor gene and inactivation of the R'
receptor gene. It also exhibited high-affinity site-i-selective
binding to the purified preparations of both R" receptor
proteins. Thus, differential regulation of various forms of
cAMP receptor proteins is involved in 8-Cl-cAMP-induced
regulation of cancer cell growth, and nuclear translocation of
Rs receptor protein appears to be an early event in such
differential regulation.
The actions of cAMP in mammalian cells are mediated
through two classes of cAMP-dependent protein kinases (1-
4), designated type I and type II. The type I and type II
enzymes have a common catalytic subunit (3, 4) but differ in
the physical properties, immunological characteristics, and
primary sequences of their cAMP-binding regulatory sub-
units (3, 4). There appears to be one principal form of the
regulatory subunit in the type I enzyme (RI) and two (or more)
types of the regulatory subunit in the type II enzyme (RI"),
expressed in a tissue-specific manner (5-8). Multiple forms of
R"I subunits have been found in normal and neoplastic tissues
of various cell types (5-10). However, very little is known
about the cellular mechanisms that control the expression of
RI or the multiple forms of RII.
We discovered (11) that differential regulation of type I
versus type II protein kinase is involved in the inhibition of
human cancer cell growth by site-selective cAMP analogs.
Depending on their substituents on the adenine ring, these
analogs selectively bind to site 1 (site B) (C-2 and C-8 analogs)
or site 2 (site A) (C-6 analog), the two known cAMP-binding
sites of protein kinase (12, 13). Moreover, among the site
1-selective analogs, C-8-thio or -halogen analogs preferen-
tially bind to site 1 of type II rather than type I protein kinase
(14, 15). This distinctive binding specificity of site-selective
cAMP analogs for two types of protein kinase, in fact,
correlated with the potency of cAMP analogs in inhibiting
growth (11).
To investigate the role of protein kinase isozymes in
growth regulation, we have examined the concentration,
subcellular localization, and transcriptional activity of genes
for these isozymes during 8-chloroadenosine 3',5'-cyclic
monophosphate (8-Cl-cAMP)-induced growth inhibition of
the LS 174T human colon cancer cell line [8-Cl-cAMP is the
most potent analog (11)]. The results were analyzed in
relation to the binding affinity of 8-Cl-cAMP for the purified
preparations of protein kinase isozymes.
MATERIALS AND METHODS
Materials. cAMP and N6,02'-dibutyryladenosine 3',5'-
cyclic monophosphate (Bt2cAMP) were obtained from Boeh-
ringer Mannheim. 8-Cl-cAMP was kindly provided by R. K.
Robins (The Nucleic Acid Research Institute, Costa Mesa,
CA). Pepstatin, antipain, chymostatin, leupeptin, and soy-
bean trypsin inhibitor were from Sigma. 8-Azidoadenosine
3',5'-cyclic [32P]monophosphate (60.0 Ci/mmol; 1 Ci = 37
GBq) and 125I-labeled protein A (30 mCi/mg) were obtained
from ICN. Eagle's minimal essential medium, fetal bovine
serum, the trypsin/EDTA solution, the penicillin-streptomy-
cin solution, L-glutamine, Hepes buffer (1 M stock solution;
pH 7.3), and minimal essential medium nonessential amino
acids were obtained from GIBCO.
Cell Culture. The LS 174T human colon carcinoma cell line
(provided by J. Greiner, National Cancer Institute) was
grown in Eagle's minimal essential medium supplemented
with 10% (vol/vol) fetal bovine serum, Eagle's minimal
essential medium nonessential amino acids, 20 mM Hepes, 2
mM glutamine, and penicillin-streptomycin; the medium was
changed every 48 hr. Growth inhibition of LS 174T cells was
induced by addition of 1-10 uM 8-Cl-cAMP (using 100 x
concentrated stock solutions) starting at 24 hr after seeding
and every 48 hr thereafter.
Preparation of Cell Cytosol and Nuclear Fraction. All
procedures were performed at 0-4°C. The cell pellets (2 x
107 cells), after two washes with isotonic phosphate-buffered
Abbreviations: RI and R", regulatory subunits of cAMP-dependent
protein kinase types I and II, respectively; Bt2cAMP, N6,02'-
dibutyryladenosine 3',5'-cyclic monophosphate; 8-Cl-cAMP, 8-
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saline, were suspended in 0.5 ml of buffer A [0.25 M
sucrose/2 mM MgCl2/1 mM CaCl2/10 mM KCl/20 mM
Tris HCl, pH 7.5/0.1 mM pepstatin/0.1 mM antipain/0.1 mM
chymostatin/0.2 mM leupeptin/aprotinin (0.4 mg/ml)/soy-
bean trypsin inhibitor (0.5 mg/ml)] and homogenized with a
Dounce homogenizer (60 strokes). The cytosols and nuclear
fractions were prepared as described (16). The purified
nuclear pellets were suspended in 200 .ul of buffer A and used
as nuclear suspension. Nuclei were judged to be free of
cytoplasmic contamination and intact cells by the absence of
glucose-6phosphate dehydrogenase activity and by phase-
contrast microscopy.
Photoaffinity Labeling of cAMP Receptor Proteins. The
photoactivated incorporation of 8-azidoadenosine 3',5'-
cyclic [32P]monophosphate was performed as described (11,
17). The samples containing 25-75 t.g of protein were sub-jected to electrophoresis in 0.05% NaDodSO4/12% poly-
acrylamide gels (18), and the separated proteins were trans-
ferred to nitrocellulose sheets (19). The sheets were air-dried
and exposed to Kodak XAR film overnight at - 20°C.
Immunoblotting of R' cAMP Receptor Protein. Cellular
proteins present in the cell cytosol and nuclear fraction (see
above) were separated and transferred to nitrocellulose
sheets (19). The sheets were first incubated with 3% (wt/vol)
bovine serum albumin (20) and then were sequentially incu-
bated with medium containing the affinity-purified monospe-
cific anti-RII antibodies [the R51 antibody, our designation(bovine heart RI, antibody, provided by R. K. Sharma,
University of Tennessee, Memphis), and the RI' antibody,
our designation (described in ref. 21 as rat skeletal muscle R"
antibody)] overnight at 4°C and with I25I-labeled protein A (5
x 105 cpm/ml) for 1 hr in an ice-water bath. The nitrocel-
lulose sheets were air-dried and exposed to Kodak XAR film
for 12-36 hr at - 200C.
Nuclear Run-off Transcription Assay. Nuclear run-off tran-
scription assays were performed as described by McKnight
and Palmiter (22). LS 174T cells were treated for various
times with 8-Cl-cAMP (10 ,uM) and compared with untreated
logarithmic-phase cells. DNA probes (2 ,ug per slot) were
blotted onto nitrocellulose by using a slot blotter (Schleicher
& Schuell). The R, probe was a 0.6-kilobase (kb) Pst I
fiagment (mouse), entirely from inside the open reading
frame (23), and the C. probe was a 0.6-kb EcoRI fragment(mouse) containing a 3' coding region and %160 base pairs of
3' nontranslating sequence (24). Plasmids of these probes
were kindly provided by S. McKnight (University of Wash-
ington, Seattle). The R' (R5,1) probe was a 1.65-kb EcoRI
fragment (human) containing the whole reading frame (except
for =80 nucleotides) and the 3' nontranslated region, and the
Rs9 (R1) probe was a 1.6-kb BamHI fragment (human)
containing half of the inside open reading frame and half of
the 3' nontranslating region. The actin probe was human (3
actin (Oncor p7000 P actin) and the pUC probe was pUC19
(Pharmacia). After overnight prehybridization, the slots were
hybridized with 32P-labeled RNA (generated from 5 x 107
nuclei per culture condition) for 48 hr at 42°C, washed,
air-dried, and exposed to Kodak XAR film for 4 days at
- 200C.
RESULTS
Photoaffinity Labeling of cAMP Receptor Proteins During
8-Cl-cAMP Treatment. Since the type I and II protein kinases
differ only in their regulatory subunits (the cAMP-binding
receptor proteins) (3, 4), by using the photoaffinity ligand
8-azidoadenosine 3',5'-cyclic [32P]monophosphate (17), we
measured the R' and R"I cAMP receptor proteins in the
cytoplasmic and nuclear fractions of the untreated control
cells and the cells treated with 8-Cl-cAMP.
As shown in Fig. 1, the untreated LS 174T cells contained
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FIG. 1. Photoaffinity labeling of cAMP receptor proteins in
cytosolic (S3) and nuclear (N) fractions ofLS 174T colon cancer cells
during 8-Cl-cAMP and Bt2cAMP treatment. Lanes: M, marker
proteins of known molecular weight; O', untreated control cells; 10'-
3d, cells treated for indicated times with 8-Cl-cAMP (10 FtM) or
Bt2cAMP (DB-cAMP) (1mM). Each lane contained 25 .g protein for
NaDodSO4/PAGE. d, Days; ', min; h, hr.
a major cAMP receptor protein (Me, 48,000), designated R'
(1), in the cytosols but not in the nuclei (lane 0'). Low
intensity bands ofMr 52,000 and Mr 56,000 receptor proteins
(R52 and R5I ) (5-10) were also detected in the cytosql and
nuclei of untreated cells (lane 0'). At 10 min after 8-Cl-cAMP
(10 ,uM) treatment, the R52 receptor protein appreciably
increased in the nuclei, reaching its maximum level by 6 hr
and remaining elevated during treatment. Concomitant with
the increase of the RI2 receptor in the nuclei, there was a
decrease ofR52 in the cytosols (30 and 60 min). At later times,
R02 in the cytosols increased (at 6 hr and 3 days). R516 also
increased in the cytosols during treatment (6 hr and 3 days),
but the nuclear R5I6 remained unchanged (Fig. 1). The R'
receptor protein in cytosol, after its transient increase (at 10
min of treatment), sharply decreased within 1 hr to a level
below that in untreated cells and remained low during
treatment (Fig. 1).
Bt2cAMP (1 mM), which does not induce growth inhibition
(11), brought about an increase in all three species ofcAMP
receptor protein in the cytosols and little or no increase in the
nuclei (Fig. 1). The autoradiograph in Fig. 1 was scanned by
densitometry; the results (Fig. 2) indicate that the R5` and R^`
in the cytosol increased 3- to 5-fold and 2- to 3-fold,
respectively, between 6 and 72 hr of 8-Cl-cAMP treatment,
while RI in the cytosol, after an initial transient increase
(2-fold) at 10 min of treatment, decreased within 1 hr to 50%
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FIG. 2. Quantification ofcAMP receptor proteins in the cytosolic
and nuclear fractions of LS 174T cells during 8-Cl-cAMP treatment.
The autoradiograph in Fig. 1 was scanned on a densitometer, and the
levels ofcAMP receptor proteins are expressed relative to the level
of RI receptor in the cytosol of untreated cells, which is set equal to
1 arbitrary unit.
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of the level in untreated cells. R52 receptor in the nuclei
increased 5- and 12-fold by 30 and 60 min of treatment,
respectively; this increase coincided well with the decrease of
RI` in the cytosol. The level of nuclear R" remained
unchanged during treatment, and R' was not detected in the
nuclei of either treated or untreated cells.
Immunoblotting Analysis of Rsn and RI cAMP Receptor
Proteins. The different behaviors observed with the photoaf-
finity labeling experiments of the two forms of RI' cAMP
receptor proteins of colon cancer cells during 8-Cl-cAMP
treatment were further examined by immunoblotting analysis
with two anti-R"I antibodies. Both antibodies are polyclonal
and affinity-purified. One antibody, prepared from rat skel-
etal muscle RI" (21), specifically cross-reacted with RI`
antigen but not with R" antigen of colon cancer cells, and
another antibody, prepared from bovine heart RI' (provided
by R. K. Sharma), demonstrated monospecificity for R5`
antigen but not for R" antigen of colon cancer cells. These
antibodies, therefore, are designated anti-RII and anti-RI
antibodies, respectively. As shown in Fig. 3, the anti-R5I
antibody detected a single band ofMr 52,000 RI" in the cytosol
of untreated cells (lane 0'). The antibody barely detected the
R5 antigen in the nuclei (lane 0'), but 10 min after 8-Cl-cAMP
treatment, the R5 antigen appreciably increased in the nuclei(lane 10'). Further increase in the R5 antigen in the nuclei
was accompanied by its decrease in the cytosols (lanes 30'
and 60'), indicating nuclear translocation of RI, receptor
protein. After 6 hr of treatment, the R,' antigen increased in
the cytosols to a level above that in the untreated cells (lanes
6h and 3d). Bt2cAMP treatment brought about a less-
pronounced increase of the R" antigen than 8-Cl-cAMP
treatment (Fig. 3).
The anti-R51 antibody detected a single band of Mr 56,000
R', in both cytosol and nuclei of untreated cells. During the
first hour of treatment with either 8-Cl-cAMP or Bt2cAMP,
there was little or no change in the amount of R' antigen in
both cytosol and nuclei (Fig. 3). At 6 hr after treatment with
8-Cl-cAMP, the RI' antigen in the cytosol increased (Fig. 3).
These data confirmed qualitatively the results of photoaffin-
ity labeling (Fig. 1). However, the magnitude of the changes
in the amounts of RI and R5 detected by the photoaffinity
labeling was considerably greater than that observed with
immunoblotting with the R" and R" antibodies. This may be
due to the known limited capacity for R" antibodies to
cross-react with the heterologous antigens (25).
Effect of 8-Cl-cAMP on the Transcriptional Activities of
cAMP Receptor Genes. We next examined the transcription of
cAMP receptor genes after 8-Cl-cAMP treatment of colon
cancer cells. Nuclear run-off transcriptional assays are
8-Cl-cAMP DB-cAMP
shown in Fig. 4. Transcription of the RI cAMP receptor gene
remained unaffected during the initial 30 min of 8-Cl-cAMP
treatment, then fell to 50%o of that in untreated cells by 1 hr.
In contrast, transcription of the RI' receptor gene increased
2-fold by 30 min and remained elevated during the course of
the experiment. Transcription of the RI' receptor gene and
the catalytic subunit gene (of protein kinase) remained
unaffected throughout the course of the experiment, but the
actin gene transcription was slightly enhanced at 30 min. A
pUC control hybridized simultaneously gave little or no
detectable signal.
DISCUSSION
We have demonstrated here that the growth inhibition in-
duced by 8-Cl-cAMP of a human colon cancer cell line
correlates with a selective modulation of various forms of
cAMP receptor proteins, the regulatory subunits of cAMP-
dependent protein kinases. Photoaffinity labeling and immu-
noblotting experiments identified three forms of cAMP re-
ceptor proteins, RI, RII, and RI', in subcellular fractions of
colon cancer cells and demonstrated changing levels of these
receptors during 8-Cl-cAMP treatment. Nuclear run-off as-
says demonstrated that these changing levels of R' and RI5
receptors are, at least in part, due to changes in gene
transcription. The transcriptional control of these receptors,
however, did not appear to be the initial event in 8-Cl-cAMP-
induced growth inhibition. Within 10 min after 8-Cl-cAMP
treatment, there was a 2-fold increase in both RI and R^I2
receptor levels even though the transcriptional changes of
these genes could not yet be detected. Thus, 8-Cl-cAMP
initially enhanced, at least transiently, the stability of RI and
R51 receptors. Change in the stability of RI after treatment of
S49 lymphoma cells with cAMP analogs (26) or an increase
in the biosynthesis of RI' during differentiation of leukemic
cells (27) has been shown.
In the present studies we report that, after initial stabili-
zation, only R15 accumulates in the nucleus. The untreated
control cells contained barely detectable levels of RI' in the
nucleus; within 10 min after 8-Cl-cAMP treatment, the RI5increased in the nucleus, and its further increase there
paralleled a decrease in the cytoplasmic RI'. Thus, 8-Cl-
cAMP selectively induced nuclear translocation of the RI
receptor in intact cells in vivo.
To correlate the binding affinity of 8-Cl-cAMP for cAMP
receptor proteins with the changes elicited by 8-Cl-cAMP of
cAMP receptor levels in colon cancer cells, we examined the
binding and activation by 8-Cl-cAMP of the purified prepa-
rations of protein kinases (Table 1). 8-Cl-cAMP demon-
strated a high-affinity binding for site 1 of the RI" receptor
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FIG. 3. Immunoblotting of R'I and RH. cAMP receptor proteins
in cytosolic (S3) and nuclear (N) fractions of LS 174T colon cancer
cells during 8-Cl-cAMP and Bt2cAMP (DB-cAMP) treatment. Immu-
noblotting of cAMP receptor proteins was performed using R^` and
RI' antibodies. Lane designations are as described in Fig. 1.
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FIG. 4. Nuclear run-off transcriptional assay. Lanes: 0', un-
treated control cells; 10', 30', and 60', cells treated with 8-Cl-cAMP
(10 ;LM) for 10 min, 30 min, and 60 min, respectively. The cDNA
probes include RI (R'), R;I (RII), R.' (R51j), C. (C), Oncor p7000
human (3 actin (actin), and pUC19 (pUC).
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Table 1. Affinity and activation potency of cAMP analogs for
protein kinase
Ki (cAMP)/Ki (analog)
RI RI, Ka (cAMP)/
Site Site Site Site Ka (analog)
Analog 1 2 1 2 I II I/II
8-Cl-cAMP 2.0 2.71 4.61 0.051 2.3 0.70 3.3
BtcAMP 0.093 3.60 0.041 0.74 0.37 0.39 0.95
Site 1 (Site B) and Site 2 (Site A) are two distinct cAMP binding
sites (12, 13) on receptor proteins (RI and RI,); the affinities ofanalogs
for site 1 and site 2 were determined by the measurement of kinetic
constants (inhibition constant, K1), and the values are expressed as
the relative affinity K; (cAMP)/K, (analog)-i.e., the ratio between
the apparent inhibition constant for cAMP and the analog, as
described (15, 28). The RII prepared from rat ovary produced similar
results. Protein kinases types I (I) and 11 (11) were prepared from
rabbit skeletal muscle and bovine heart, respectively, as described
(29). The relative activation Ka (cAMP)/Ka (analog), where Ka is the
concentration of cAMP or analog sufficient for half-maximum
activation of the protein kinase (15, 30), is reported for protein
kinases types I and II. The ratio of the relative activations of protein
kinases types I and II is also presented (1/11). BtcAMP, N6-
butyryladenosine 3',5'-cyclic monophosphate.
(4.6-fold more than cAMP) while exhibiting a low-affinity
binding for site 2 of RI' (5% that of cAMP). Therefore, it has
a 90-fold greater affinity for site 1 than site 2 of R" receptor
protein compared with cAMP.
8-Cl-cAMP exhibited a lower affinity and a change in its
site selectivity for RI receptor. It showed a higher-affinity
binding for site 2 than site 1 (2.7- versus 2.0-fold that of
cAMP). Thus, 8-Cl-cAMP belongs to a specific class of
cAMP analogs, such as 8-piperidinoadenosine 3',5'-cyclic
monophosphate (15), that demonstrates a differential site
selectivity toward R' versus R" receptors.
In the activation of protein kinase, 8-Cl-cAMP showed a
3.3-fold greater potency for type I protein kinase than for type
II protein kinase (Table 1). N6-Butyryladenosine 3',5'-cyclic
monophosphate, which induces little or no growth inhibition
(11), demonstrated a higher binding affinity for the RI than the
RI' receptor, and it activated with equal potency both type I
and II protein kinase (Table 1).
These results indicate that the growth-inhibitory effect of
cAMP analogs does not correlate with their potency for protein
kinase activation per se but rather depends on their binding
affinity for the receptor proteins, the regulatory subunits of
protein kinases. 8-Cl-cAMP, the potent growth inhibitor of
human colon cancer cells (11), exhibited a high-binding affinity
for the Ri receptor and enhanced the stability, nuclear trans-
location, and synthesis of RI, receptor protein.
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